• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

PBM re­form un­like­ly to at­tach to short-term spend­ing bill as shut­down looms

5 months ago
Pharma
FDA+

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

5 months ago
Pharma
FDA+

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

5 months ago
FDA+

Rhythm re­ceives ex­pand­ed ap­proval for ge­net­ic obe­si­ty drug

5 months ago
Pharma
FDA+

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

5 months ago
R&D
FDA+

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

5 months ago
R&D

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

5 months ago
Financing
Startups

Ap­plied Ther­a­peu­tics CEO steps down af­ter rare dis­ease drug re­jec­tion

5 months ago
People
FDA+

Idor­sia’s Tryvio deal de­lay; Galectin’s liv­er drug dis­ap­points

5 months ago
News Briefing

Com­mure's lat­est ac­qui­si­tion sends fol­low-up texts to pa­tients

5 months ago
Deals
Health Tech

Trac­er Biotech­nolo­gies rais­es $10M, part­ners with As­traZeneca

5 months ago
Deals
Diagnostics

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

5 months ago
Peer Review

Aa­di starts from scratch as it sells as­sets, li­cens­es AD­Cs and rais­es new funds

5 months ago
Deals
R&D

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

5 months ago
Financing
Startups

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

5 months ago
R&D

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

5 months ago
FDA+

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

5 months ago
FDA+

Xcov­ery nabs first FDA ap­proval for lung can­cer drug

5 months ago
Pharma
FDA+

Mesoblast wins long-await­ed ap­proval for cell ther­a­py

5 months ago
Pharma
Cell/Gene Tx

Pay­ers gen­er­al­ly meet drug price watch­dog's 'fair ac­cess' stan­dards, re­port says

5 months ago
Pharma
FDA+

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

5 months ago
R&D
Pharma

What health tech star­tups can ex­pect in 2025

5 months ago
Health Tech

Gilead deep­ens its stake in As­sem­bly Bio­sciences; NGM li­cens­es out MASH drug

5 months ago
News Briefing

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

5 months ago
Pharma
Health Tech
First page Previous page 61626364656667 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times